Compare CULP & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CULP | BDSX |
|---|---|---|
| Founded | 1972 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.7M | 53.0M |
| IPO Year | N/A | 2020 |
| Metric | CULP | BDSX |
|---|---|---|
| Price | $3.81 | $7.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 20.7K | ★ 55.0K |
| Earning Date | 12-10-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $207,391,000.00 | $80,173,000.00 |
| Revenue This Year | $1.93 | $20.75 |
| Revenue Next Year | $2.77 | $25.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 22.29 |
| 52 Week Low | $3.42 | $3.44 |
| 52 Week High | $5.94 | $32.20 |
| Indicator | CULP | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 41.41 | 52.38 |
| Support Level | $3.78 | $7.68 |
| Resistance Level | $3.95 | $8.69 |
| Average True Range (ATR) | 0.13 | 0.67 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 16.05 | 58.95 |
Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.